Please login to the form below

Not currently logged in
Email:
Password:

Gates Foundation and China launch USD 50m AIDS campaign

The Bill & Melinda Gates Foundation will launch a USD 50m HIV and AIDS prevention campaign in partnership with the Chinese government and other organisations

The Bill & Melinda Gates Foundation will launch a USD 50m HIV and AIDS prevention campaign in partnership with the Chinese government and non-governmental organisations in the region.

The partnership will expand prevention programmes in 12 major cities, including Beijing, Shanghai, Guangzhou and the island province of Hainan, with the aim of referring people at high-risk of HIV infection to voluntary counselling and testing centres.

The programme will serve groups including men who have sex with men (MSM), injecting drug users and sex workers. Around USD 20m of the initial grant will go to the Chinese Ministry of Health and the remaining USD 30m will be used to provide grants to local, national and international NGOs.

The programme will include training to reduce high-risk behaviour, public education campaigns and expanding HIV testing programmes. The China campaign will be similar to the Gates Foundation's Avahan programme in India.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Numbers, navigation, and narratives: digital storytelling in medical communications
Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...
Is this common data mistake killing your digital patient recruitment?
Without realising, you could be falling into the trap of using social data — insights into recent, relevant trends and topics — to inspire your content. Hold up. That sounds...
Stick or Twist? Healthcare brands in a (post) COVID-19 world
...